APETx2 is a peptide isolated from the sea anemone Anthopleura elegantissima. It is the most potent and selective inhibitor of acid-sensing ion channel 3 (ASIC3) and it is currently in preclinical studies as a novel analgesic for the treatment of chronic inflammatory pain. As a peptide it faces many challenges in the drug development process, including the potential lack of stability often associated with therapeutic peptides. In this study we determined the susceptibility of wild-type APETx2 to trypsin and pepsin and tested the applicability of backbone cyclisation as a strategy to improve its resistance to enzymatic degradation. Cyclisation with either a six-, seven- or eight-residue linker vastly improved the protease resistance of APETx2 but substantially decreased its potency against ASIC3. This suggests that either the N- or C-terminus of APETx2 is involved in its interaction with the channel, which we confirmed by making N- and C-terminal truncations. Truncation of either terminus, but especially the N-terminus, has detrimental effects on the ability of APETx2 to inhibit ASIC3. The current work indicates that cyclisation is unlikely to be a suitable strategy for stabilising APETx2, unless linkers can be engineered that do not interfere with binding to ASIC3.
References
[1]
Lax, R. The Future of Peptide Development in the Pharmaceutical Industry. PharManufacturing: The International Peptide Review 2010, 10–15.
[2]
King, G.F. Venoms as a platform for human drugs: Translating toxins into therapeutics. Expert Opin. Biol. Ther. 2011, 11, 1469–1484, doi:10.1517/14712598.2011.621940.
Chiras, D.D. Nutrition and digestion. In Human Biology, 7th ed.; Jones & Bartlett Learning: Mississanga, Canada, 2011; pp. 89–117.
[5]
Clark, R.J.; Fischer, H.; Dempster, L.; Daly, N.L.; Rosengren, K.J.; Nevin, S.T.; Meunier, F.A.; Adams, D.J.; Craik, D.J. Engineering stable peptide toxins by means of backbone cyclization: Stabilization of the α-conotoxin MII. Proc. Natl. Acad. Sci. USA 2005, 102, 13767–13772.
[6]
Linde, Y.; Ovadia, O.; Safrai, E.; Xiang, Z.; Portillo, F.P.; Shalev, D.E.; Haskell-Luevano, C.; Hoffman, A.; Gilon, C. Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers 2008, 90, 671–682, doi:10.1002/bip.21057.
[7]
Adessi, C.; Frossard, M.J.; Boissard, C.; Fraga, S.; Bieler, S.; Ruckle, T.; Vilbois, F.; Robinson, S.M.; Mutter, M.; Banks, W.A.; et al. Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer’s disease. J. Biol. Chem. 2002, 278, 13905–13911.
[8]
Lewis, R.J.; Garcia, M.L. Therapeutic potential of venom peptides. Nat. Rev. Drug Discov. 2003, 2, 790–802, doi:10.1038/nrd1197.
Vetter, I.; Davis, J.L.; Rash, L.D.; Anangi, R.; Mobli, M.; Alewood, P.F.; Lewis, R.J.; King, G.F. Venomics: A new paradigm for natural products-based drug discovery. Amino Acids 2011, 40, 15–28, doi:10.1007/s00726-010-0516-4.
[11]
Yamaguchi, Y.; Hasegawa, Y.; Honma, T.; Nagashima, Y.; Shiomi, K. Screening and cDNA cloning of Kv1 potassium channel toxins in sea anemones. Mar. Drugs 2010, 8, 2893–2905, doi:10.3390/md8122893.
[12]
Diochot, S.; Baron, A.; Rash, L.D.; Deval, E.; Escoubas, P.; Scarzello, S.; Salinas, M.; Lazdunski, M. A new sea anemone peptide, APETx2, inhibits ASIC3, a major acid-sensitive channel in sensory neurons. EMBO J. 2004, 23, 1516–1525, doi:10.1038/sj.emboj.7600177.
[13]
Sluka, K.A.; Winter, O.C.; Wemmie, J.A. Acid-sensing ion channels: A new target for pain and CNS diseases. Curr. Opin. Drug Discov. Devel. 2009, 12, 693–704.
Deval, E.; No？l, J.; Lay, N.; Alloui, A.; Diochot, S.; Friend, V.; Jodar, M.; Lazdunski, M.; Lingueglia, E. ASIC3, a sensor of acidic and primary inflammatory pain. EMBO J. 2008, 27, 3047–3055, doi:10.1038/emboj.2008.213.
[16]
Karczewski, J.; Spencer, R.H.; Garsky, V.M.; Liang, A.; Leitl, M.D.; Cato, M.J.; Cook, S.P.; Kane, S.; Urban, M.O. Reversal of acid-induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2. Br. J. Pharmacol. 2010, 161, 950–960, doi:10.1111/j.1476-5381.2010.00918.x.
[17]
Theralpha, Product THA902. Available online: http://www.theralpha.com/index.php?page=tha902 (accessed on 4 May 2012).
[18]
Jensen, J.E.; Durek, T.; Alewood, P.F.; Adams, D.J.; King, G.F.; Rash, L.D. Chemical synthesis and folding of APETx2, a potent and selective inhibitor of acid sensing ion channel 3. Toxicon 2009, 54, 56–61, doi:10.1016/j.toxicon.2009.03.014.
[19]
Chagot, B.; Escoubas, P.; Diochot, S.; Bernard, C.; Lazdunski, M.; Darbon, H. Solution structure of APETx2, a specific peptide inhibitor of ASIC3 proton-gated channels. Protein Sci. 2005, 14, 2003–2010.
[20]
Clark, R.J.; Jensen, J.; Nevin, S.T.; Callaghan, B.P.; Adams, D.J.; Craik, D.J. The engineering of an orally active conotoxin for the treatment of neuropathic pain. Angew. Chem. Int. Ed. Engl. 2010, 49, 6545–6548.
[21]
Kwan, A.H.; Mobli, M.; Gooley, P.R.; King, G.F.; Mackay, J.P. Macromolecular NMR spectroscopy for the non-spectroscopist. FEBS J. 2011, 278, 687–703.
[22]
King, G.F.; Shih, Y.L.; Maciejewski, M.W.; Bains, N.P.; Pan, B.; Rowland, S.L.; Mullen, G.P.; Rothfield, L.I. Structural basis for the topological specificity function of MinE. Nat. Struct. Biol. 2000, 7, 1013–1017, doi:10.1038/80917.
[23]
Schanda, P.; Brutscher, B. Very fast two-dimensional NMR spectroscopy for real-time investigation of dynamic events in proteins on the time scale of seconds. J. Am. Chem. Soc. 2005, 127, 8014–8015, doi:10.1021/ja051306e.
[24]
Anangi, R.; Chen, C.C.; Lin, Y.W.; Cheng, Y.R.; Cheng, C.H.; Chen, Y.C.; Chu, Y.P.; Chuang, W.J. Expression in Pichia pastoris and characterization of APETx2, a specific inhibitor of acid sensing ion channel 3. Toxicon 2010, 56, 1388–1397, doi:10.1016/j.toxicon.2010.08.004.
[25]
Lingueglia, E. Acid-sensing ion channels in sensory perception. J. Biol. Chem. 2007, 282, 17325–17329, doi:10.1074/jbc.R700011200.
[26]
Deval, E.; No？l, J.; Gasull, X.; Delaunay, A.; Alloui, A.; Friend, V.; Eschalier, A.; Lazdunski, M.; Lingueglia, E. Acid-sensing ion channels in postoperative pain. J. Neurosci. 2011, 31, 6059–6066, doi:10.1523/JNEUROSCI.5266-10.2011.
[27]
Blanchard, M.G.; Rash, L.D.; Kellenberger, S. Inhibition of voltage-gated Na(+) currents in sensory neurones by the sea anemone toxin APETx2. Br. J. Pharmacol. 2012, 165, 2167–2177.
Shiomi, K. Novel peptide toxins recently isolated from sea anemones. Toxicon 2009, 54, 1112–1118, doi:10.1016/j.toxicon.2009.02.031.
[30]
Lesner, A.; ？？gowska, A.; Wysocka, M.; Rolka, K. Sunflower trypsin inhibitor 1 as a molecular scaffold for drug discovery. Curr. Pharm. Des. 2011, 17, 4308–4317, doi:10.2174/138161211798999393.
[31]
Gould, A.; Ji, Y.; Aboye, T.L.; Camarero, J.A. Cyclotides, a novel ultrastable polypeptide scaffold for drug discovery. Curr. Pharm. Des. 2011, 17, 4294–4307, doi:10.2174/138161211798999438.
[32]
Halai, R.; Callaghan, B.; Daly, N.L.; Clark, R.J.; Adams, D.J.; Craik, D.J. Effects of cyclization on stability, structure, and activity of α-conotoxin RgIA at the α9α10 nicotinic acetylcholine receptor and GABAB receptor. J. Med. Chem. 2011, 13, 6984–6992.
[33]
Lovelace, E.S.; Armishaw, C.J.; Colgrave, M.L.; Wahlstrom, M.E.; Alewood, P.F.; Daly, N.L.; Craik, D.J. Cyclic MrIA: A stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter. J. Med. Chem. 2006, 49, 6561–6568.
[34]
Schn？lzer, M.; Alewood, P.; Jones, A.; Alewood, D.; Kent, S.B. In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. Int. J. Pept. Protein Res. 1992, 40, 180–193.
[35]
Fu, T.J.; Abbott, U.R.; Hatzos, C. Digestibility of food allergens and nonallergenic proteins in simulated gastric fluid and simulated intestinal fluid-a comparative study. J. Agric. Food Chem. 2002, 50, 7154–7160, doi:10.1021/jf020599h.
[36]
Tugyi, R.; Uray, K.; Iván, D.; Fellinger, E.; Perkins, A.; Hudecz, F. Partial D-amino acid substitution: Improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide. Proc. Natl. Acad. Sci. USA 2005, 102, 413–418.
